Interleukin-2 Receptor and Ovarian Cancer
Author Information
Author(s): O.J. Owens, C. Taggart, R. Wilson, J.J. Walker, J.H. McKillop, J.H. Kennedy
Primary Institution: Glasgow Royal Infirmary
Hypothesis
The study investigates whether serum levels of interleukin-2 receptor (IL-2R) can differentiate between malignant and benign ovarian tumors.
Conclusion
Serum IL-2R levels are significantly elevated in patients with malignant ovarian tumors compared to both normal controls and benign ovarian tumors.
Supporting Evidence
- IL-2R levels were significantly elevated in the malignant group compared to the control group.
- IL-2R levels were significantly elevated in the malignant group compared to the benign group.
- The median IL-2R level in malignant ovarian tumors was 1,267 U ml-1.
Takeaway
The study found that women with ovarian cancer have higher levels of a specific protein in their blood compared to women without cancer.
Methodology
Patients were recruited based on clinical diagnosis, and serum IL-2R levels were measured using an enzyme immunoassay.
Limitations
The study did not assess the correlation between IL-2R levels and disease staging or differentiation within the malignant group.
Participant Demographics
The study included 78 women, with 30 diagnosed with malignant ovarian tumors, 11 with benign tumors, and 28 age-matched controls.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.0001
Want to read the original?
Access the complete publication on the publisher's website